Eleni Theocharidou, Michael A. Heneghan – 12 June 2018 – Autoimmune liver diseases (AILDs) can recur following liver transplantation (LT) despite immunosuppressive therapy, with implications for graft survival. Although the evidence is not robust, disease recurrence seems to occur in the presence of less intense and/or steroid‐free immunosuppression (IS) in particular in the case of autoimmune hepatitis (AIH). The main risk factor for AIH recurrence is the severity of disease activity in the explant and potential donor/recipient human leukocyte antigen D‐related 3 (DR3) mismatch.

Rinaldo Pellicano, Marilena Durazzo – 11 June 2018

Fumiko Chino, Kimberly Ellen Pollis, Steve Choi, Joseph K Salama, Manisha Palta – 11 June 2018

Bharat Bhushan, John W. Stoops, Wendy M. Mars, Anne Orr, William C. Bowen, Shirish Paranjpe, George K. Michalopoulos – 11 June 2018 – TCPOBOP (1,4‐Bis [2‐(3,5‐Dichloropyridyloxy)] benzene) is a constitutive androstane receptor (CAR) agonist that induces robust hepatocyte proliferation and hepatomegaly without any liver injury or tissue loss. TCPOBOP‐induced direct hyperplasia has been considered to be CAR‐dependent with no evidence of involvement of cytokines or growth factor signaling.

Saumya Pandey – 11 June 2018

Paulo N. Martins – 11 June 2018

Fumiko Chino, Kimberly Ellen Pollis, Steve Choi, Joseph K Salama, Manisha Palta – 11 June 2018

Naim Alkhouri, Fred Poordad, Eric Lawitz – 7 June 2018 – Nonalcoholic fatty liver disease (NAFLD) is considered the hepatic manifestation of insulin resistance, which is the hallmark of type 2 diabetes (T2D). NAFLD is a known risk factor for developing T2D and has a very high prevalence in those with existing T2D. The diabetes spectrum includes several conditions from prediabetes to T2D to insulin‐dependent diabetes leading to macrovascular and microvascular complications.

6 June 2018

6 June 2018